Peptides DB
Research-centric peptide and protocol reference hub
Study 14 of 14Afamelanotide literatureThe Journal of dermatology · RCT · Phase 3

Study Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria.

The APOLLO study is evaluating bitopertin in patients with EPP and XLP, with 183 participants randomized to assess its safety and efficacy over 24 weeks.

Read at The Journal of dermatologyAdd to compare

Where it sits

this study against the rest of the afamelanotide corpus
3
Preclinical
7
Observational
0
Open-label
3
Randomised · this one
1
Reviews

Summary and findings

The study investigates the safety, tolerability, and efficacy of bitopertin in adults and adolescents with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). Participants aged ≥12 years were randomized to receive either 60 mg of bitopertin or placebo for 24 weeks. The study design and baseline characteristics of participants are described.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
183 participants randomized.n=183Phase 3

Abstract

The authors’ words, as The Journal of dermatology supplied them

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double-blind, placebo-controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once-daily oral bitopertin 60 mg or placebo over 24 weeks. Co-primary endpoints are percent change in whole blood metal-free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease-modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.

Background

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are conditions marked by the accumulation of protoporphyrin IX (PPIX), leading to severe skin reactions and potential liver complications. Prior research has indicated that Glycine transporter 1 (GlyT1) plays a role in heme biosynthesis, making it a target for therapeutic intervention. This study is significant as it aims to evaluate bitopertin, an investigational GlyT1 inhibitor, in a Phase 3 setting, which could provide insights into its potential as a disease-modifying therapy.

Methods

The APOLLO study is a global, randomized, double-blind, placebo-controlled Phase 3 trial. Eligible participants were aged 12 years and older with a confirmed diagnosis of EPP or XLP, randomized 1:1 to receive either 60 mg of oral bitopertin or placebo once daily for 24 weeks. Co-primary endpoints include the percent change in whole blood metal-free PPIX and average monthly total time in sunlight on days without pain from phototoxic reactions.

Results

Not reported in abstract.

Interpretation

The findings regarding participant demographics and baseline characteristics align with previous studies on EPP and XLP, suggesting that the study population is representative of the broader patient population. However, the abstract does not provide specific results on the primary endpoints, limiting the ability to assess the clinical significance of bitopertin's effects. The study's design and the inclusion of adolescents are noteworthy, but the lack of reported outcomes raises questions about the immediate implications for clinical practice.

Key findings

  • 199 patients screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia.
  • 183 participants were randomized.
  • Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White.
  • 93% of participants had EPP, while 7% had XLP.
  • 60% had not received prior treatment for EPP; 28% previously received afamelanotide.

Limitations

  • Not yet reported efficacy and safety outcomes.
  • Ongoing study with results expected after 24 weeks.
  • No specific statistical analyses provided in abstract.

Elsewhere in the Afamelanotide corpus

AStudy Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria.The Journal of dermatology · 2026 · 183 participants randomized.HumanBAdjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.Photochemistry and photobiology · 2026 · n=8 · Statistically significant improvement in QoL on Day 60, p=0.014.HumanBAdjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.Photochemistry and photobiology · 2026 · n=8 · Statistically significant improvement in QoL on Day 60, p=0.014.HumanBLong-term causes of death in 888,003 ischemic stroke patients in Thailand: a nationwide retrospective study with 18-year follow-up.Annals of medicine · 2026 · n=888003 · Overall mortality was 47.6% among 888,003 patients with ischemic stroke.HumanBAcute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023 · n=9 · UVR-erythema dose response area-under-curve decreased from mean 3.5 pre to 2.7 post afamelanotide, P=0.018.HumanCMultienzyme supplementation improves bone strength in nutrient-restricted broilers without altering locomotor ability or pectoral myopathy severity.British poultry science · 2026 · n=1400 · Enzyme supplementation increased bone strength, with PPNC2 restoring mechanical resistance to values comparable to those of the PC (p<0.001).Animal